KRYS (STOCKS)
Krystal Biotech, Inc. Common Stock
$319.920000
+1.950000 (+0.61%)
Prev close: $317.970000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Biotechnology
- CEO
- Krish S. Krishnan
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $9,431.18M
- Employees
- 275
- P/E (TTM)
- 42.50
- P/B (TTM)
- 7.33
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
7
Strong Buy
9
Buy
2
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Mar 2026 (Q1)
|
$1.83 | $1.45 | +0.3814 | +26.33% |
|
Dec 2025 (Q4)
|
$1.70 | $1.44 | +0.2633 | +18.33% |
|
Sep 2025 (Q3)
|
$2.66 | $1.11 | +1.5527 | +140.22% |
|
Jun 2025 (Q2)
|
$1.29 | $1.15 | +0.1397 | +12.14% |
Financial Statements
| Revenues | $417.30M |
| Benefits Costs and Expenses | $209.99M |
| Costs And Expenses | $209.99M |
| Operating Expenses | $238.66M |
| Selling, General, and Administrative Expenses | $155.20M |
| Research and Development | $59.12M |
| Other Operating Expenses | $24.34M |
| Operating Income/Loss | $178.64M |
| Income/Loss From Continuing Operations After Tax | $225.03M |
| Income/Loss From Continuing Operations Before Tax | $207.32M |
| Income Tax Expense/Benefit | -$17.72M |
| Net Income/Loss | $225.03M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | $225.03M |
| Net Income/Loss Available To Common Stockholders, Basic | $225.03M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | $7.75 |
| Diluted Earnings Per Share | $7.48 |
| Basic Average Shares | 87,202,000 |
| Diluted Average Shares | 90,211,000 |
| Assets | $1.40B |
| Current Assets | $1.02B |
| Cash | $823.40M |
| Inventory | $42.65M |
| Other Current Assets | $153.70M |
| Noncurrent Assets | $377.23M |
| Fixed Assets | $153.58M |
| Other Non-current Assets | $223.64M |
| Liabilities | $120.24M |
| Current Liabilities | $107.80M |
| Accounts Payable | $4.09M |
| Other Current Liabilities | $103.71M |
| Noncurrent Liabilities | $12.44M |
| Equity | $1.28B |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $1.28B |
| Liabilities And Equity | $1.40B |
| Net Cash Flow From Operating Activities | $250.28M |
| Net Cash Flow From Operating Activities, Continuing | $250.28M |
| Net Cash Flow From Investing Activities | -$67.23M |
| Net Cash Flow From Investing Activities, Continuing | -$67.23M |
| Net Cash Flow From Financing Activities | $10.71M |
| Net Cash Flow From Financing Activities, Continuing | $10.71M |
| Exchange Gains/Losses | -$1.22M |
| Net Cash Flow | $192.54M |
| Net Cash Flow, Continuing | $193.76M |
| Comprehensive Income/Loss | $222.25M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | $223.02M |
| Other Comprehensive Income/Loss | $183.92M |